Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2024-04-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 22nd meeting of the 4th Supervisory Board of the company. It details the meeting date, attendance, and the approval of various reports and proposals including the 2023 Annual Report, 2024 Q1 Report, 2023 Supervisory Board Work Report, 2023 Financial Statements, Profit Distribution Plan, Internal Control Self-Evaluation Report, and other governance matters. The document does not contain the full reports themselves but rather the resolutions approving them and notes that these will be submitted to the 2023 Annual General Meeting for further approval. The document length is relatively short (2525 characters) and serves as an official announcement of meeting decisions rather than the reports themselves. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement of supervisory board meeting resolutions and approvals, not the full Annual Report or other detailed reports.
2024-04-25 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding a change in accounting policy, specifically related to the adoption of a new accounting standard issued by the Ministry of Finance. It details the reasons for the change, the impact on financial statement items, and includes opinions from the audit committee, board of directors, and supervisory board. The document is relatively short (2721 characters) and does not contain full financial statements or comprehensive financial data. It is not a full annual or interim report, nor is it a certification or a regulatory filing of a different nature. The document is an official announcement about a change in accounting policy, which is a regulatory announcement but does not fit into categories like Annual Report, Interim Report, or Audit Report. Given the nature and length, it best fits into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-04-25 Chinese
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2023 annual financial settlement report of a company, including detailed financial data such as total assets, liabilities, equity, revenue, profit, and cash flow for the year ending December 31, 2023. It mentions that the financial statements have been audited by an accounting firm with an unqualified opinion. The document contains substantive financial data and analysis for the full fiscal year 2023. The length is 1570 characters, which is relatively short but contains actual financial data, not just an announcement or a certification. Therefore, it is a full Annual Report type document rather than just an announcement or certification. The presence of audited financial statements and comprehensive financial results aligns with the definition of an Annual Report (10-K). FY 2023
2024-04-25 Chinese
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special report on the independence self-assessment of independent directors of the company, referencing regulatory guidelines and internal company rules. It does not contain financial data, audit results, or management discussion of financial performance. It is a compliance-related report focusing on governance and director independence. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-25 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized report titled '葵花药业集团股份有限公司 非经营性资金占用及其他关联资金往来情况的专项报告' which translates to a special report on non-operating fund occupation and other related party fund transactions for the year 2023. It includes detailed financial data such as balances, transactions, and interest related to these funds. The report references an audit opinion issued on the 2023 financial statements and complies with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is not a full annual report or interim report but a standalone audit-related special report focusing on specific financial and regulatory compliance matters. It is not an announcement or a brief summary but contains substantive financial data and audit verification. Therefore, it fits the category of an Audit Report / Information (AR). The document length is 2587 characters, which is short but contains detailed tables and audit statements, indicating it is the report itself, not just an announcement. FY 2023
2024-04-25 Chinese
关于2024年度向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's plan to apply for a comprehensive credit facility from banks for the year 2024. It details the proposed credit limit, validity period, types of credit services, and authorization for the application process. It also mentions that the matter has been approved by the board and will be submitted to the shareholders' meeting for approval. There are no financial statements, audit information, or detailed financial results included. The document is a financing update related to capital structure and credit facilities, not a full financial report or regulatory certification. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report, so it is not RPA or RNS.
2024-04-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.